


We are a biotech company developing personalized immune therapies (DCVax®) to treat solid tumor cancers. facebook.com/Northwest.Bioth…


Join @NorthwestBio on Sunday, June 3, at 4:15 (CT) at #ASCO2018 as Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will discuss the interim data that was published on May 29 from the Company’s Phase 3 trial of DCVax®-L for newly diagnosed #Glioblastoma brain #cancer.

.@NorthwestBio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for #Glioblastoma Brain #Cancer. nwbio.com/nwbio-announces-sc…

The Poster & accompanying presentation will be posted on the $NWBO website following the presentation at nwbio.com/webcasts/ #DCVax

$NWBO presentation at Int'l Cancer Immunotherapy Conference will be presented in the 6:45-8:45pm ET Session A today ow.ly/Sijcq

$NWBO CTO Dr. Marnix Bosch to present a new DCVax-Direct poster at Inaugural Int'l Cancer Immunotherapy Conference ow.ly/Sii17

$NWBO to Present at 4th Annual @SMIpharm Cancer Vaccines Conference in London Today at 1:30pm BST (8:30am ET) ow.ly/SbPY2 #DCVAX

Press Release: NW Bio Confirms Phase III Trial of DCVax®-L for GBM Brain Cancer Is Ongoing finance.yahoo.com/news/nw-bi… $NWBO #NWBO

Promising new data on Phase I trial of DCVax-Direct for direct injection into all types of inop. solid tumors ow.ly/NJxN7 $NWBO

Findings to date from $NWBO's DCVax-Direct Phase I trial relating to immunological responses include the following: ow.ly/NMTzL

$NWBO looks forward to proceeding w/ Phase II trials applying lessons learned from this informative Phase I trial ow.ly/NJyoa

Data to date from DCVax-direct Phase I trial: 86% of Phase I patients treated w/ preferred method still alive ow.ly/NJxSW $NWBO

ICYMI: Watch Dr. Marnix L. Bosch give an overview of $NWBO's #DCVax direct Phase 1 trial here: ow.ly/NFICA #ASCO15

Press Release: $NWBO Announces Data to Date From #DCVax-Direct Phase I Trial ow.ly/NJwJN #cancer


Happy to be at #ASCO15 - stop by and see us! http://t.co/4mFz1rdrdm